Literature DB >> 22721707

Factor H autoantibodies in membranoproliferative glomerulonephritis.

Timothy H J Goodship1, Isabel Y Pappworth, Tibor Toth, Mark Denton, Kris Houlberg, Frances McCormick, David Warland, Iain Moore, Eva-Maria Hunze, Scott J Staniforth, Christine Hayes, Danielle Paixão Cavalcante, David Kavanagh, Lisa Strain, Andrew P Herbert, Christoph Q Schmidt, Paul N Barlow, Claire L Harris, Kevin J Marchbank.   

Abstract

Factor H autoantibodies are found in ~10% of aHUS patients. Most are associated with complete deficiency of factor H related proteins 1/3 and bind to the C terminal recognition domain. MPGN, like aHUS, is characterised by complement activation. In this study we, therefore, examined the hypothesis that factor H autoantibodies are associated with MPGN. We screened sera from 16 MPGN patients and 100 normal controls using ELISA and detected strongly positive IgG factor H autoantibodies in 2 patients. One patient had type II (DDD) MPGN (male aged 24 yrs) with C3NeF and the other type I (female aged 26 yrs) with no detectable C3NeF. We identified the binding site of the autoantibodies using small SCR domain fragments in the ELISA and showed that the autoantibodies in both patients bound predominately to the N terminal complement regulatory domain of factor H. We measured CFHR 1/3 copy number using MLPA and showed that both patients had 2 copies of CFHR1 and 3. Finally, we examined the functionality of detected factor H autoantibodies using purified patient IgG and observed increased haemolysis when purified IgG from both patients was added to normal human sera prior to incubation with rabbit red blood cells. Thus, in a cohort of MPGN patients we have found a high titre of functionally significant factor H autoantibodies in two patients with MPGN. Antibody depleting therapy may have a role in such patients and we suggest that screening for factor H autoantibodies should be undertaken in all patients with MPGN.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721707     DOI: 10.1016/j.molimm.2012.05.009

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  34 in total

1.  Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).

Authors:  Rachael Watson; Emma Wearmouth; Amy-Claire McLoughlin; Arthur Jackson; Sophie Ward; Paula Bertram; Karim Bennaceur; Catriona E Barker; Isabel Y Pappworth; David Kavanagh; Susan M Lea; John P Atkinson; Timothy H J Goodship; Kevin J Marchbank
Journal:  Mol Immunol       Date:  2014-08-21       Impact factor: 4.407

2.  Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Authors:  Caroline Rousset-Rouvière; Mathilde Cailliez; Florentine Garaix; Daniele Bruno; Daniel Laurent; Michel Tsimaratos
Journal:  Pediatr Nephrol       Date:  2014-01-10       Impact factor: 3.714

3.  Circulating complement levels and C3 glomerulopathy.

Authors:  Fernando C Fervenza; Sanjeev Sethi
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-23       Impact factor: 8.237

4.  A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.

Authors:  Sophie Chauvet; Lubka T Roumenina; Sarah Bruneau; Maria Chiara Marinozzi; Tania Rybkine; Elizabeth C Schramm; Anuja Java; John P Atkinson; Jean Claude Aldigier; Frank Bridoux; Guy Touchard; Veronique Fremeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2015-10-15       Impact factor: 10.121

Review 5.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

Review 6.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

Review 7.  Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-07-06

Review 8.  Making sense of the spectrum of glomerular disease associated with complement dysregulation.

Authors:  Sally Ann Johnson; Edwin K S Wong; C Mark Taylor
Journal:  Pediatr Nephrol       Date:  2013-07-14       Impact factor: 3.714

Review 9.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

Review 10.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.